Abstract
Introduction

1
Targeting what has been recently coined as super-enhancers has emerged as a powerful 2 therapeutic strategy in cancer treatment (1) . Super 
17
Cell lines were treated with 0.1 to 6,000 nM OTX015 for 72 h and cell viability was assessed 18 using the MTT assay (Roche, Mannheim, Germany) as previously described (13). GraphPad
19
Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA) was used to calculate 50% 20 inhibition of growth (IC 50 ) and maximal effect of the highest OTX015 dose (6 µM). Apoptosis
21
and cell proliferation were assessed after 72 h treatment with 250 and 500 nM OTX015 using 
25
(100 µg/ml) to stain DNA and RNAse (1 mg/ml). Cellular DNA content was analyzed on a 26 FC500 flow cytometer (Beckman Coulter, Jersey City, NJ, USA). Cell survival after treatment 27 with 250, 500, and 1,000 nM OTX015 or 0.2 % DMSO was also evaluated in real-time using
28
Research. assays was verified by qPCR using positive control primers for the human RPL10 promoter.
20
ChIP-seq libraries were sequenced on the HiSeq next-generation sequencing platform.
21
Samples had >40 million raw reads that were trimmed of low-quality and adapter sequences.
22
Read alignment to the human hg19 genome assembly was performed using bowtie2 with 23 default settings, which achieved >93 % sequence mapping. Genome browser maps were 24 created by extending reads to 200 bp and computing the density using BEDTools (25 
18
Real-time reverse transcriptase PCR
19
Total RNA was isolated from cells using the RNeasyMini kit (Qiagen) and cDNA synthesis 20 was generated using the SuperScript reverse transcription kit (Invitrogen, Darmstadt,
21
Germany). Quantitative mRNA expression levels were monitored using Assays-on- 
27
(http://www.biogazelle.com).
28
Research. 
26
Tumors from OTX015-treated IMR-5 xenografts also showed a significant increase in the 27 proportion of apoptotic cells (Suppl. 
21
The effect of BRD4 inhibition in neuroblastoma cells has previously been attributed to MYCN 22 repression (11). We set out to test the existing hypothesis that BET protein inhibition mainly (Fig. 3a) . As an orthogonal model we Indeed, in LSL-MYCN;Dbh-iCre derived mNB-A1 cells, MYCN protein levels remained stable 8 even after treatment with OTX015 (Fig. 3d) . Interestingly, in vitro treatment of the mNB-A1 9 cell line with OTX015 significantly reduced cell viability as did JQ1 treatment (Fig. 3c) . Mice 14 Again, MYCN expression was not affected by OTX015 treatment (Fig. 3g) . Concurrently, the 15 fraction of apoptotic cells was significantly increased in the LSL-MYCN;Dbh-iCre tumors,
16
while the fraction of proliferating cells was reduced ( Fig. 3h and 3i) . Together, OTX015
17
showed therapeutic efficacy in both murine neuroblastoma GEMM models and human cells 
patterns compared to DMSO-treated control cells (Fig. 4a) . Genes that were differentially and MYC pathways (Fig. 4b) . The same gene sets were enriched among the genes 
27
super-enhancers in the IMR-5 genome using an algorithm proposed by Whyte et al. (Fig. 5a) 
28
Research. Fig. 5a and Suppl. Fig. 5 ). We hypothesized that super-enhancer-associated genes would Fig. 5c ). The cumulative distribution of gene expression changes was also 6 significantly shifted towards a stronger repression of genes associated with super-enhancers 7 (Fig. 5b) . Expression of genes associated with super-enhancers was significantly lower than 8 genes not associated with super-enhancers after treatment with either OTX015 or JQ1 (Fig.   9 5c). Consistent with this, ChIP-Seq detected a significant decrease in BRD4 binding to 10 chromatin, particularly at super-enhancer regions ( Fig. 5d-f (Fig. 5g)(23, 27) . This 
6
This further sustains our hypothesis that inhibiting BRD4 with OTX015 blocks BRD4 and P- 
20
Considering recent discoveries implicating BRD4 in super-enhancer regulation, we set out to 21 understand the extent to which inhibiting BRD4-chromatin binding would specifically disrupt 
10
Remarkably, such signature scores are also capable of identifying poor outcome in patients 11 with tumors expressing low MYCN transcript levels but high nuclear MYCN protein levels 12 (27). These patients would likely also benefit from BET protein inhibitor treatment and this 13 could be applicable in other tumor types in which MYCN is the driving oncogenes.
14
The results we report here provide conclusive evidence that BET protein inhibition disrupts 
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